UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [(18)F]ISO-1

PloS one, 2013-09, Vol.8 (9), p.e74188

2013

Volltextzugriff (PDF)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ

PloS one, 2015-10, Vol.10 (10), p.e0141849

2015

Volltextzugriff (PDF)

Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine‐induced urinary bladder cancers

International journal of cancer, 2008-11, Vol.123 (10), p.2254-2259

2008

Volltextzugriff (PDF)

Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models

Cancer prevention research (Philadelphia, Pa.), 2015-03, Vol.8 (3), p.231-239

2015

Volltextzugriff (PDF)

Short-term Modulation of Cell Proliferation and Apoptosis and Preventive/Therapeutic Efficacy of Various Agents in a Mammary Cancer Model

Clinical cancer research, 2007-09, Vol.13 (18), p.5488-5496

2007

Volltextzugriff (PDF)

Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis

Clinical cancer research, 2004-10, Vol.10 (19), p.6703-6709

2004

Volltextzugriff (PDF)

Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors

Cancer prevention research (Philadelphia, Pa.), 2010-01, Vol.3 (1), p.73-81

2010

Volltextzugriff (PDF)

Preventive effects of Polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols

Molecular cancer therapeutics, 2007-07, Vol.6 (7), p.2022-2028

2007

Volltextzugriff (PDF)

Gene Expression Profiling of Chemically Induced Rat Bladder Tumors

Neoplasia (New York, N.Y.), 2007-03, Vol.9 (3), p.207-221

2007

Volltextzugriff (PDF)

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes

Molecular cancer therapeutics, 2008-04, Vol.7 (4), p.972-979

2008

Volltextzugriff (PDF)

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models

Oncology reports, 2018-09, Vol.40 (3), p.1545-1553

2018

Volltextzugriff (PDF)

Naproxen Induces Cell-Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting PI3K

Cancer prevention research (Philadelphia, Pa.), 2014-02, Vol.7 (2), p.236-245

2014

Volltextzugriff (PDF)

Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression

Cancer prevention research (Philadelphia, Pa.), 2018-10, Vol.11 (10), p.595-606

2018

Volltextzugriff (PDF)

Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide

Molecular cancer therapeutics, 2006-04, Vol.5 (4), p.1060-1072

2006

Volltextzugriff (PDF)

Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers

Cancer prevention research (Philadelphia, Pa.), 2020-03, Vol.13 (3), p.273-282

2020

Volltextzugriff (PDF)

Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers

Cancer prevention research (Philadelphia, Pa.), 2020-03, Vol.13 (3), p.283-290

2020

Volltextzugriff (PDF)

Screening Agents for Preventive Efficacy in a Bladder Cancer Model: Study Design, End Points, and Gefitinib and Naproxen Efficacy

The Journal of urology, 2010-04, Vol.183 (4), p.1598-1603

2010

Volltextzugriff (PDF)

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations

Molecular cancer therapeutics, 2006-04, Vol.5 (4), p.1073-1078

2006

Volltextzugriff (PDF)

Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy

Cancer prevention research (Philadelphia, Pa.), 2015-04, Vol.8 (4), p.296-302

2015

Volltextzugriff (PDF)

Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats

Cancer research (Chicago, Ill.), 2000-10, Vol.60 (20), p.5599-5602

2000

Volltextzugriff (PDF)

Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model

Cancer prevention research (Philadelphia, Pa.), 2014-02, Vol.7 (2), p.246-254

2014

Volltextzugriff (PDF)

5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?

Cancer prevention research (Philadelphia, Pa.), 2016-07, Vol.9 (7), p.616-623

2016

Volltextzugriff (PDF)

Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers

Cancer prevention research (Philadelphia, Pa.), 2009-11, Vol.2 (11), p.951-956

2009

Volltextzugriff (PDF)

Lipoxygenase Inhibitors as Potential Cancer Chemopreventives

Cancer epidemiology, biomarkers & prevention, 1999-05, Vol.8 (5), p.467-483

1999

Volltextzugriff (PDF)

Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer

Cancer prevention research (Philadelphia, Pa.), 2012-02, Vol.5 (2), p.248-259

2012

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Aktive Filter

ThemaRats

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(128)

Publikationsform

Artikel
(134)

Sprache

Englisch
(134)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

Animals
(134)
Science & Technology
(125)
Life Sciences & Biomedicine
(123)
Oncology
(85)
Biological And Medical Sciences
(79)
Medical Sciences
(74)
Male
(69)
Female
(68)
Rats, Inbred F344
(59)
Rats, Sprague-Dawley
(51)
Tumors
(47)
Anticarcinogenic Agents - Pharmacology
(32)
Carcinogenesis, Carcinogens And Anticarcinogens
(31)
Dose-Response Relationship, Drug
(27)
Chemical Agents
(26)
Toxicology
(24)
Mammary Neoplasms, Experimental - Chemically Induced
(22)
Mice
(22)
Cytochrome P-450 Enzyme System - Biosynthesis
(21)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [(18)F]ISO-1

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ

Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine‐induced urinary bladder cancers

Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models

Short-term Modulation of Cell Proliferation and Apoptosis and Preventive/Therapeutic Efficacy of Various Agents in a Mammary Cancer Model

Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis

Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors

Preventive effects of Polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols

Gene Expression Profiling of Chemically Induced Rat Bladder Tumors

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes

Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models

Naproxen Induces Cell-Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting PI3K

Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression

Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide

Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers

Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers

Screening Agents for Preventive Efficacy in a Bladder Cancer Model: Study Design, End Points, and Gefitinib and Naproxen Efficacy

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations

Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy

Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats

Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model

5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?

Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers

Lipoxygenase Inhibitors as Potential Cancer Chemopreventives

Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer

Aktive Filter

Suchergebnisse filtern